Neurology prior authorization at Premera Blue Cross
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Premera Blue Cross neurology PA at a glance
Premera Blue Cross reviews neurology PA submissions against its medical policy library, with rules drawn primarily from AAN (American Academy of Neurology) + AHS (American Headache Society) for migraine. Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet — what to send
- MS or migraine diagnosis with ICD-10
- MS: MRI brain/spine within 6-12 months
- Migraine: headache diary (paper or app) covering ≥3 months
- Prior preventives with drug, dose, duration, and reason for discontinuation
- Disease severity score (EDSS for MS; MIDAS/HIT-6 for migraine)
Common denial patterns to pre-empt
Patterns observed in neurology across payers, and where Premera Blue Cross's book of business overlaps:
- MS: McDonald criteria not documented
- MS: step therapy through DMTs before high-efficacy
- Migraine: insufficient prior preventive trials (typically 2 from different classes)
- Migraine: monthly migraine day frequency not documented
- Functional impairment / disability not characterised
- Step therapy via Express Scripts
- Specialty drug prior auth
Appeal angles when Premera Blue Cross denies
- AAN guideline citation by year
- MRI documentation of new lesions / clinical relapse for MS
- Headache diary documenting ≥4 monthly migraine days for CGRP class
- Failed step-therapy preventives with dose/duration/AE for each
Peer-to-peer prep
- Pull the most recent MRI report (lesion count, T2/FLAIR burden, new enhancement)
- Quote the AAN practice advisory by year
- For migraine: bring headache diary entries — payers reject 'frequent migraines' without quantified MMDs
- For high-efficacy MS DMTs: state explicitly which DMTs were tried and the failure (relapse, MRI activity, AE)
Drug-specific PA criteria at Premera Blue Cross
Deep dives on each drug's PA criteria at Premera Blue Cross:
Frequently asked questions
What documentation does Premera Blue Cross need for neurology prior authorizations?
Premera Blue Cross's PA packet for neurology typically includes: MS or migraine diagnosis with ICD-10; MS: MRI brain/spine within 6-12 months; Migraine: headache diary (paper or app) covering ≥3 months; Prior preventives with drug, dose, duration, and reason for discontinuation. AAN (American Academy of Neurology) + AHS (American Headache Society) for migraine citations strengthen the submission.
What's the turnaround at Premera Blue Cross?
Premera Blue Cross standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which neurology drugs does Premera Blue Cross most often PA-restrict?
Top targets in neurology: ocrelizumab, natalizumab, ofatumumab, erenumab, galcanezumab. Each follows the per-drug step therapy + documentation requirements published in Premera Blue Cross's medical policy library.
How do I prep a peer-to-peer with Premera Blue Cross in neurology?
Pull the most recent MRI report (lesion count, T2/FLAIR burden, new enhancement) Quote the AAN practice advisory by year Have the policy URL and the patient's chart open before the call.
Generate a Neurology PA packet
Open ApprovalHelp — generate a neurology PA packet tailored to Premera Blue Cross's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com